Data underlying the study is available at: <https://e-space.mmu.ac.uk/id/eprint/623717> (DOI: <https://doi.org/10.23634/MMUDR.00623717>).

Introduction {#sec006}
============

In the past, attitudes to physical activity recommendation for older adults was simply that "some physical activity is better than none" \[[@pone.0224223.ref001]\]. More recently, guidelines have been more detailed so that in the United Kingdom for instance, the recommendations are that older adults should engage in at least 150 minutes per week of moderate to vigorous physical activity (MVPA) through the accumulation of bouts of at least 10 minutes (~10~MVPA) \[[@pone.0224223.ref001]\]. Reaching this target is thought to reduce the risk of cardiovascular mortality by 35% \[[@pone.0224223.ref002]\]. However based on objective monitoring of physical behaviour within older adult cohorts, where cardiovascular disease is one of the leading causes of death \[[@pone.0224223.ref003]\], less than 15% of the population are thought to attain the 150 minutes per week ~10~MVPA target \[[@pone.0224223.ref004], [@pone.0224223.ref005]\]. With such low attainment rates for the ~10~MVPA recommendation within older adult populations, it is pertinent to find and advocate, alternative physical behaviour interventions that could improve cardiovascular health for adults who do not or cannot attain the ~10~MVPA recommendation.

Epidemiological studies have suggested that physical behaviour at intensities below MVPA could modulate cardiovascular disease risk factors, such as plasma triglycerides and glucose \[[@pone.0224223.ref006]--[@pone.0224223.ref008]\]. However, implementation of these findings by end-users would require a change in their habitual physical behaviour profile that, in a 24-hour day, would reduce the amount of time they could spend engaging in other physical behaviours. Ultimately, physical behaviour change is not just about the newly engaged physical behaviour but also about the physical behaviour that is being replaced, and the collective effects that the changes in these two physical behaviour intensities have on health status. Until recently, physical behaviour epidemiology had failed to account for the time limiting impact of a 24-hour day when predicting how a change in a physical behaviour may affect health status.

Isotemporal Substitution Modelling is a relatively new form of statistical analysis within PB research, first used to predict weight change in middle-aged women (25--42 years) \[[@pone.0224223.ref009]\]. Since this seminal research, 80 publications have utilised ISM (PubMed, retrieved 26/02/2019). However, there is an apparent lack of studies that examine the associations between time reallocation and cardio-metabolic profile in older adult populations \[[@pone.0224223.ref010]\].

The adoption of isotemporal substitution modelling (ISM) \[[@pone.0224223.ref009]\] by physical behaviour researchers has now made it possible to determine how health status may be affected by replacing the time spent engaging in one physical behaviour intensity with another physical behaviour intensity. The growing evidence base of ISM has highlighted that as little as a 10-minute change in physical behaviour profile can affect cardio-metabolic status \[[@pone.0224223.ref011]--[@pone.0224223.ref020]\]. However, previous ISM studies have 'objectively' estimated the engagement in the physical behaviour spectrum with hip, waist, or wrist mounted accelerometers, which are arguably less accurate in terms of classifying posture and thus, cannot reliably distinguish between sedentary behaviour (SB) and standing, for instance, which have shown to have opposing effects on health status \[[@pone.0224223.ref012], [@pone.0224223.ref021]--[@pone.0224223.ref023]\].

Thus, the aim of the current cross-sectional study was to model how older adults' cardio-metabolic endocrine profiles would change if they replaced an hour per day (1 hr·day^-1^) of a physical behaviour intensity with 1 hr·day^-1^ of another physical behaviour of a different intensity (e.g. replace SB with light intensity physical activity \[LIPA\]). It was hypothesised that replacing 1 hr·day^-1^ of physical behaviour for one of a higher intensity (in terms of metabolic demands) would improve cardio-metabolic status and *vice versa*.

Materials and methods {#sec007}
=====================

Ethical approval was granted by the Manchester Metropolitan University Exercise and Sports Science Ethics Sub-Committee (Approval Code: 03.11.14(i)). Written informed consent was provided by all participants prior to data collection. Participants were recruited from older adult community groups (e.g. Bridge clubs and Bowls clubs) within a rural, affluent, and highly educated county in England \[[@pone.0224223.ref024], [@pone.0224223.ref025]\] Older adults (≥ 60 years old) were eligible for the study if they were independently mobile (did not require walking aids), were not diabetic, had no current/past history of neurological disorders likely to limit mental/physical function at the time of the study, were not suffering from an un-treated cardiovascular disease. Ninety-three older adults (73.8 ± 6.23 years, 60--89 years, 55% female) were recruited between January 2015 and June 2016. Participants visited the laboratory on two occasions, separated by at least seven days.

First laboratory visit {#sec008}
----------------------

During the first laboratory visit, participants were familiarised with the testing protocol that they would undergo during the second laboratory visit. Demographic information, such as height, weight, and current medical prescriptions were also collected. Medication use was presented in the following formats: the number of different medications prescribed for daily use, which could directly influence cardiovascular profile (Directly CVD Meds \[n·day^-1^\]), the number of different medications prescribed for daily use, which could (in)directly influence cardiovascular profile ((In)directly CVD Meds \[n·day^-1^\]), the sum daily dosage of inflammatory, (in)directly influencing cardiovascular profile medication (CVD Meds \[mg·day^-1^\]), daily dose of blood pressure medication (BP Meds \[mg·day^-1^\]), daily dose of lipid-lowering medication (Lipid-Lowering Meds \[mg·day^-1^\]).

Participants were fitted with a thigh-mounted triaxial accelerometer (GENEActiv Original, Activinsights Ltd, Kimbolton, UK) on the dominant leg (anterior aspect, 50% of greater trochanter to femoral condyle distance) using two waterproof adhesive patches (3M Tegaderm Film, North Ryde, Australia) to be worn for seven consecutive free-living days. The full details of the accelerometer programming can be found in \[[@pone.0224223.ref026]\]. Briefly, an in-house developed data analysis software (the Cheshire Algorithm for Sedentarism \[CAS\]) \[[@pone.0224223.ref027]\] utilised 60 Hertz sampling frequency, 10 second epoch accelerometer data to determine participant time spent in SB (seated or reclined posture, ≤1.5 Metabolic Equivalent Tasks \[METs\]), Standing (upright posture, ≤1.5 METs), LIPA (upright posture 1.5--3.0 METs), Sporadic MVPA (sMVPA, upright posture, ≥3.0 METS, for \<10 consecutive minutes), and ~10~MVPA (upright posture, ≥3.0 METS, for ≥10 consecutive minutes. Nighttime sleeping hours (i.e. daytime naps not included) was self-reported using a written sleep-diary and included within CAS analysis. Where sleeping hours was not reported, raw accelerometer data was cross-referenced to identify prolonged nocturnal reclined posture. Thus, an estimate of when a participant went to bed and woke up on the monitored week was always possible. Three participants were removed from analysis for having \<6 days of accelerometer data.

Second laboratory visit {#sec009}
-----------------------

Participants arrived at the laboratory in an overnight (\>10 hours) fasted, hydrated state. Participants refrained from taking medication on the morning of the laboratory visit until the completion of a 10 mL venous blood sample donation. Hydration, medication intake and a light breakfast were then allowed immediately after said sampling.

Whole blood cardio-metabolic analysis {#sec010}
-------------------------------------

Immediately following blood donation (i.e. within 3 mins), whole blood analyses of total cholesterol, triglyceride, glucose, and glycated haemoglobin (HbA1c, sub-sample of *n* = 33) using three Accutrend Plus monitor devices and test strips (Roche Diagnostics Limited, Welwyn Garden City, UK) and one HemoCue 501 device and test cartridge (HemoCue, Ängelholm, Sweden), respectively, were carried out. Analyses were performed in triplets and averaged for total cholesterol, triglyceride, and glucose whereas only a single sample was analysed for HbA1c. Accutrend monitors have shown no difference in comparison to clinical laboratory methods in the measurement of total cholesterol, triglyceride, and glucose concentration \[[@pone.0224223.ref028]\]. Furthermore, the HemoCue 501 has shown good reliability (Coefficient of Variation \[CV\] \<5/0%) and validity (Bland-Altman: 4.4 \[95%CI -7.3, 16.2\] mmol∙mol^-1^) compared to high performance liquid chromatography ion exchange \[[@pone.0224223.ref029]\]

The remainder of the whole blood sample was allowed to clot whilst placed on crushed ice in a 10 mL Serum Vacutainer (Becton Dickinson, New Jersey, USA) for less than two hours before centrifugation at 1687 G for five minutes (Z380, Hermle, Gosheim, Germany). Serum was extracted into 1.0 mL aliquots (Eppendorf Ltd, Hamburg, Germany) and stored at -20 ºC until further analyses.

Serum cardio-metabolic analyses {#sec011}
-------------------------------

Concentration of serum lipoprotein lipase (LPL), procollagen III N-terminal propeptide (PIIINP), and interleukin-6 (IL-6) were determined using commercially available enzyme-linked immunosorbent (ELISA) assay kits (LPL: Cell Biolabs Inc., California, USA, PIIINP: Biomatik, Delaware, USA, IL-6: high-sensitivity, Bio-Techne, Minnesota, USA) with a two-fold sample dilution. Manufacturer intra-assay sample CV was 4% (\<13% in-house) for LPL, \<10% (6.5--9.6% in-house) for PIIINP, and 7.8% (7.4--9.2% in-house) for IL-6. A 96-well spectrophotometer (EL808, BioTek, Vermont, USA) connected to a computer running Gen5 c 1.11 software (BioTek, Vermont, USA) was used to derive protein concentration data.

Statistical analyses {#sec012}
--------------------

SPSS version 22 (IBM, New York, USA) was used for statistical modelling. Physical behaviour parameters, measured in mean hrs∙day^-1^ (SB, Standing, LIPA, sMVPA, and ~10~MVPA) and the summation of these parameters (Total PB) were used for ISM. Pearson correlation was used to assess multicollinearity between physical behaviour parameters and total PB; no adjustment to the data was made if multicollinearity was present. The largest case of collinearity was between SB and LIPA (*r*^*2*^ = -0.69), which was below the suggested limits of collinearity (*r*^*2*^\>0.9) \[[@pone.0224223.ref030]\]. To illustrate the effect on cardio-metabolic parameters with the replacement of one hour of a physical behaviour with another, the replaced physical behaviour parameter was removed from the linear regression model (forced entry) (i.e. replace SB model: Intercept + (*ẞ1* х Standing) + (*ẞ2* х LIPA) + (*ẞ3* х sMVPA) + (*ẞ4* х ~10~MVPA) + (*ẞ5* х Total PB) + Covariates + Error) \[[@pone.0224223.ref030]\]. Significant predictors in the model illustrate that the replacement of a physical behaviour with the significant physical behaviour could have a predicted effect on the cardio-metabolic parameter. To standardise reporting of the ISM outcome, the removed physical behaviour is mentioned first. For example, *'the replacement of one hour of SB with standing reduced total cholesterol'* means that SB engagement has been reduced by one hour and replaced with one hour of standing.

ISM was performed without (Model 1) and with (Model 2) covariate adjustment (Directly CVD Meds \[n·day^-1^\], \[In\]directly CVD Meds \[n·day^-1^\], CVD Meds \[mg·day^-1^\], BP Meds \[mg·day^-1^\], Lipid-Lowering Meds \[mg·day^-1^\]). A covariate was included in the ISM if a forced entry linear regression model had highlighted an association between the covariate and the respective cardio-metabolic parameter in a preliminary analysis of the dataset. These covariates were chosen as they have previously been shown to influence the cardio-metabolic parameters of interest in the current study \[[@pone.0224223.ref031]--[@pone.0224223.ref034]\]. Cardio-metabolic data were naturally LOG transformed if they violated normal distribution (total cholesterol, triglyceride, LPL, IL-6, and PIIINP). Data are presented as beta coefficient (95% Confidence Interval \[CI\]) unless stated otherwise. Statistical significance was set at *p*≤0.05.

Results {#sec013}
=======

To enhance reader experience, this study features augmented reality. To access this feature, please download HP Reveal (Hewlett-Packard, California, USA) from your smart phone app store and create a free account. Search for, then follow DrDeclanRyan, scan your phone camera over the figures within this study to view the augmented reality attachments.

The sample population characteristics are detailed below ([Table 1](#pone.0224223.t001){ref-type="table"}). Over 50% of the sample population had lipid markers that were above international recommended thresholds (triglyceride: 56%, total cholesterol: 66%). Whilst for glucose markers, 35% of the sample population had a higher than recommended glucose concentration but no participants had an above threshold HbA1c percentage. Twenty-one percent of the participants were not prescribed medication, whilst 30% and 60% of the population had been prescribed lipid-lowering and blood pressure medication, respectively. Notably, mean ~10~MVPA was below 10 mins·day^-1^ ([Table 1](#pone.0224223.t001){ref-type="table"}), this was because 49 participants failed to register a single bout of 10-continuous minutes of MVPA across seven-days of monitoring.

10.1371/journal.pone.0224223.t001

###### Participant demographics for the study sample.

Displayed as Mean (Standard Deviation) unless stated otherwise.

![](pone.0224223.t001){#pone.0224223.t001g}

  Variable                                                                      Pooled Population
  ----------------------------------------------------------------------------- --------------------
  *n*                                                                           93
  Female (%)                                                                    55
  Age (years)                                                                   73.8 (6.22)
  Height (m)                                                                    1.65 (0.08)
  Mass (kg)                                                                     75.9 (13.1)
  BMI (kg·m^2^)                                                                 27.9 (4.71)
  **Covariates**                                                                
  Directly CVD Meds (*n*∙day^-1^)[†](#t001fn001){ref-type="table-fn"}           1.17 (1.52)
  (In)directly CVD Meds (*n*∙day^-1^)[‡](#t001fn002){ref-type="table-fn"}       1.62 (1.81)
  Inn+ (In)directly CVD Meds (mg∙day^-1^)[¥](#t001fn003){ref-type="table-fn"}   157.86 (486.49)
  BP Meds (mg∙day^-1^)                                                          9.81 (50.79)
  Lipid-Lowering Meds (mg∙day^-1^)                                              8.12 (16.58)
  **Cardio-metabolic Parameters**                                               
  Triglyceride (mmol∙l^-1^)                                                     1.77 (0.81)~m~
  Total Cholesterol (mmol∙l^-1^)                                                5.44 (1.39)~m~
  Glucose (mmol∙l^-1^)                                                          5.72 (1.10)~m~
  HbA1c (%)                                                                     5.29 (0.31)
  LPL (pg∙mL^-1^)                                                               113.02 (147.80)~m~
  IL-6 (pg∙mL^-1^)                                                              2.72 (2.77)~m~
  PIIINP (pg∙mL^-1^)                                                            229.21 (247.97)~m~
  **Physical Behaviour Parameters**                                             
  SB (hrs∙day^-1^)                                                              9.65 (1.33)
  Standing (hrs∙day^-1^)                                                        1.09 (0.41)
  LIPA (hrs∙day^-1^)                                                            1.97 (0.63)
  sMVPA (hrs∙day^-1^)                                                           2.57 (0.64)
  ~10~MVPA (hrs∙day^-1^)                                                        0.08 (0.20)~m~
  Total PB (hrs∙day^-1^)                                                        15.4 (4.77)~m~

† Participants are currently prescribed an amount of medication that reduces the risk or treats CVD (i.e. statins, warfarin)

‡ Participants are currently prescribed a medication that may affect the cardiovascular system either directly or as a side effect

¥ Participants are currently prescribed a medication that may affect the cardiovascular system either directly or as a side effect, including inflammatory medication. ~m~ Median (IR).

It is pertinent to note that for simplicity, only significant models are presented in the results section. The complete set of the results is displayed in the Supporting Information ([S1](#pone.0224223.s001){ref-type="supplementary-material"}--[S7](#pone.0224223.s007){ref-type="supplementary-material"} Tables). Significant ISM was present for total cholesterol and triglyceride (Figs [1](#pone.0224223.g001){ref-type="fig"} and [2](#pone.0224223.g002){ref-type="fig"}) i.e. two out of a possible seven cardio-metabolic markers that were monitored.

![Significant changes in total cholesterol concentration with the replacement of 1 hr·day^-1^ of PB with another.\
Model 1: no covariate adjustment. Model 2: adjusted for directly CVD medication (n∙day^-1^) and (in)directly CVD medication (n∙day^-1^). Data points represent LOG data (from left to right): -95%CI, beta coefficient, +95%CI. p≤0.05. This figure is Augmented Reality Ready, download HP Reveal from your Smart Phone App Store to access the embedded videos.](pone.0224223.g001){#pone.0224223.g001}

![Significant changes in triglyceride concentration with the replacement of 1 hr·day^-1^ of PB with another.\
Model 1: no covariate adjustment. Data points represent LOG data (from left to right): -95%CI, beta coefficient, +95%CI. p≤0.05. This figure is Augmented Reality Ready, download HP Reveal from your Smart Phone App Store to access the embedded videos.](pone.0224223.g002){#pone.0224223.g002}

Total cholesterol {#sec014}
-----------------

Without covariate adjustment, the replacement of 1 hr·day^-1^ of SB with standing was associated with a reduction in total cholesterol by (anti-logged data) 1.14 (95%CI 1.28, 1.01) mmol∙l^-1^ ([Fig 1](#pone.0224223.g001){ref-type="fig"}). This is clinically relevant as a 0.5 mmol∙l^-1^ decrease in total cholesterol concentration is associated with a 17% decreased risk in coronary heart disease mortality \[[@pone.0224223.ref035]\]. The replacement of LIPA with standing was associated with a reduction in total cholesterol (anti-logged data, 1.25 \[95%CI 1.49, 1.04\] mmol∙l^-1^) ([Fig 1](#pone.0224223.g001){ref-type="fig"}). Finally, the replacement of sMVPA with standing was associated with a reduction in total cholesterol by (anti-logged data) 1.15 (95%CI 1.32, 1.01) mmol∙l^-1^ ([Fig 1](#pone.0224223.g001){ref-type="fig"}). With adjustment for directly CVD medication (*n*∙day^-1^) and (in)directly CVD medication (*n*∙day^-1^), all significant models (model 1) remained significant (model 2) ([Fig 1](#pone.0224223.g001){ref-type="fig"}).

Triglyceride {#sec015}
------------

There were no covariates for triglyceride. Most notably, the replacement of any PB with ~10~MVPA was associated with a decrease in triglyceride concentration by similar amounts, as the change in triglyceride concentration fell between (anti-logged data) 1.89--2.03 (95%CI range: 3.16, 1.17) mmol∙l^-1^ ([Fig 2](#pone.0224223.g002){ref-type="fig"}). On the other hand, the replacement of ~10~MVPA with any other PB (excluding sMVPA) was associated with an increase in triglyceride concentration by similar amounts (anti-logged data, beta coefficient range: 1.79--1.86 \[95%CI range: 1.17, 2.94\]) mmol∙l^-1^ ([Fig 2](#pone.0224223.g002){ref-type="fig"}). These results are clinically relevant as a 1.0 mmol∙l^-1^ increase in triglyceride concentration is associated with a 14% (95%CI 5, 28%, male) - 37% (95%CI 13, 66%, female) relative risk increase in CVD prevalence \[[@pone.0224223.ref036]\].

Discussion {#sec016}
==========

The objective of this study was to mathematically model, using ISM, how a strictly older adult population (60--89 years) could change their cardio-metabolic profile through changes in PB engagement. It was hypothesised that substitution of SB or PA with PA of higher intensity may theoretically improve cardio-metabolic profile whilst the substitution of a higher intensity PA with a lower intensity PA or SB would theoretically worsen cardio-metabolic profile, as has been illustrated previously in young-middle and middle-older adult populations \[[@pone.0224223.ref011], [@pone.0224223.ref012], [@pone.0224223.ref014]\]. Indeed the hypotheses were confirmed as the replacement of SB with standing was associated with a decrease in total cholesterol concentration and the replacement of any PB with ~10~MVPA was associated with a decrease in triglyceride concentration. Therefore, the results of the current study suggested that using PB interventions could be a useful method for the prevention and treatment of lipid disorders, such as atherosclerosis, which when it manifests in the coronary arteries, is responsible for 44.5% of CVD deaths in UK older adults \[[@pone.0224223.ref003]\]. However, at face value, some of the total cholesterol results were counterintuitive as the replacement of sMVPA and LIPA with standing was, in fact, associated with a decrease in total cholesterol concentration.

The two sides to standing {#sec017}
-------------------------

Total cholesterol is comprised of high-density lipid cholesterol (HDL-C), low-density lipid cholesterol (LDL-C), and triglyceride. The theoretical reduction in total cholesterol concentration, after sMVPA and LIPA were replaced with standing in the current model, may be a product of lowered HDL-C, thereby suggesting that standing negatively affects cardio-metabolic status. Indeed, one month of detraining following a LIPA intervention in older adults (mean age 75.5±5.60 years) has been reported to decrease HDL-C concentration whilst LDL-C and triglyceride remained constant \[[@pone.0224223.ref037]\].

Not only did the modelled replacement of sMVPA and LIPA with standing theoretically reduce total cholesterol within the current study but a decrease in total cholesterol concentration was also associated with SB being replaced with standing. It could be postulated that standing is positively affecting lipoprotein profile in this case, possibly by reducing non HDL-C lipoproteins. This postulation is in agreement with a previous four-day intervention study in young adults (21±2 years), which found non-HDL-C concentration decreased from 2.94±0.47 to 2.65±0.48 mmol·l^-1^ following the replacement of six hours of SB with two hours of standing and four hours of walking, compared to a 14 hrs·day^-1^ of SB day \[[@pone.0224223.ref023]\]. Meanwhile, there was also a non-significant trend for total cholesterol to decrease from 4.20±0.67 to 3.96±0.50 mmol·l^-1^ (*p* = 0.17) \[[@pone.0224223.ref023]\]. Although ISM can suggest an intervention, it cannot state how long an intervention can take to have a significant effect on health status. However, along with the results of Duvivier, Schaper \[[@pone.0224223.ref023]\], it could be suggested that the replacement of one hour of SB with standing could reduce total cholesterol if the intervention lasts longer than four days.

Overall, these findings suggested that standing could affect circulating cholesterol, differentially, depending on which PB parameter it is displacing and thus facilitates the prediction of individualised outcomes for PB change interventions.

Benefits of prolonged moderate activity {#sec018}
---------------------------------------

Performing longer bouts of MVPA may induce a chronic physiological effect that protects against physical inactivity, as total cholesterol concentration modelling was predicted to decrease when sMVPA, but not ~10~MVPA, was replaced with standing within the current study. In terms of the time frame for adaption in cholesterol profile with the introduction of physical inactivity, previous studies have varied considerably depending on what duration of MVPA bouts were being undertaken prior to physical inactivity. For example, the lipoprotein profile of trained endurance rowers took 29 weeks, following the cessation of exercise (performed in bouts of MVPA ≥10 mins), to become significantly different. Specifically, HDL-C decreased from 0.92±0.09 pre detraining to 0.81±0.11 mmol·l^-1^ post detraining (*p*\<0.05, a 0.004 mmol·l^-1^ reduction per week) \[[@pone.0224223.ref038]\]. Whereas, it took only four weeks until HDL-C concentration was significantly reduced (from 1.42±0.05 to 1.34±0.05 mmol·l^-1^, *p*\<0.05, a 0.02 mmol·l^-1^ reduction per week) following the cessation of a four-month interval training intervention (performed in bouts of MVPA \<10 mins, 4 × 4 mins MVPA, 3 mins rest) \[[@pone.0224223.ref039]\]. Despite these previous finding being reported in middle-aged adults, there are similarities in cardio-metabolic change with a reduction in MVPA when compared with the current study. It is likely that engagement in prolonged bouts of MVPA (~10~MVPA) would be beneficial in the preservation of long-term cholesterol profile should an older adult be temporarily forced into a physically inactive lifestyle (i.e. prolonged bedrest due to illness or injury).

Furthermore, the associated reduction in fasted triglyceride concentration when any PB, including sMVPA, was replaced with ~10~MVPA in the current study, also strengthens the theorem that prolonged MVPA bouts would improve/maintain lipoprotein profile. In addition, the lack of association on fasted triglyceride concentration when SB was replaced for PA suggests that a focus on reducing physical inactivity is more important than SB reduction when attempting to improve triglyceride profile. Whereas the lack of effect on fasted total cholesterol when ~10~MVPA is replaced in the model (and improvements when SB is replaced) could suggest that SB reduction as opposed to physical inactivity reduction could be more important for total cholesterol profile improvements, possibly due to the effects on LDL-C and HDL-C pathway alluded to above. However, intervention studies would be required to confirm or deny the hypotheses engendered through the present modelling exercises.

No effect of physical behaviour on lipoprotein lipase {#sec019}
-----------------------------------------------------

Pre-heparin serum LPL concentration was measured within the current study and it is thought to represent whole-body LPL production and the systemic potential to hydrolyse triglycerides \[[@pone.0224223.ref040], [@pone.0224223.ref041]\]. Additionally, pre-heparin serum LPL has been shown to be inversely related to the progression of coronary artery disease in young/middle--older aged populations (Hitsumoto, Ohsawa \[[@pone.0224223.ref042]\]: 22--79 years, Rip, Nierman \[[@pone.0224223.ref043]\]: 45--79 years), highlighting that pre-heparin serum LPL is anti-atherogenic. Furthermore, exercise has been shown to increase LPL within humans and rats in all age groups \[[@pone.0224223.ref044]--[@pone.0224223.ref046]\], thus suggesting that PA can protect against atherosclerosis through the mediation of the LPL pathway. Conversely, the results of the current modelling study suggested that the replacement of any PB may not necessarily affect serum LPL concentration. A possible explanation for these results is that pre-heparin serum LPL is representative of whole-body LPL \[[@pone.0224223.ref040], [@pone.0224223.ref041]\], in which, the expression of LPL within certain sites can portray a pro-atherogenic effect (e.g. artery wall) \[[@pone.0224223.ref047]\]. Therefore, the representation of both pro and anti-atherogenic LPL within pre-heparin serum LPL may cause 'noise' within the ISM, thus nullifying any effects on pro or anti-atherogenic LPL that may exist with PB change. Furthermore, this 'noise' is likely to be more pronounced in the older adult population, who already have an increased serum LPL concentration compared to middle aged adults \[[@pone.0224223.ref048]\] and are more likely to show progression of atherosclerosis, which has been positively associated with LPL concentration within the aorta \[[@pone.0224223.ref049]\].

Not statistically significant but clinically significant results {#sec020}
----------------------------------------------------------------

Although the confidence interval range of some of the cardio-metabolic markers suggested no association with PB substitution, there were beta co-efficients and confidence intervals that were large enough to suggest some clinical relevance. Previous findings from Emerging Risk Factors Collaboration \[[@pone.0224223.ref050]\] suggested that a 1 mmol·l^-1^ increase in fasting plasma glucose was associated with a 12% increase in hazard ratio for coronary heart disease incidents. Within the findings of the current study, replacing ~10~MVPA with SB had a beta-coefficient of 0.38 mmol·l^-1^ and an upper confidence interval limit of 2.04 mmol·l^-1^ ([S4 Table](#pone.0224223.s004){ref-type="supplementary-material"}). This may suggest that some older adults will experience adverse effects of replacing ~10~MVPA with SB. It could be that the design of this study may not have been sufficient to detect statistically significant associations, but it should not mean that future studies dismiss further research.

Strengths and limitations {#sec021}
-------------------------

The current study's strength include the utilisation of a week-long thigh-mounted accelerometer to accurately detect all physical behaviours including sedentary behaviour, every 60 seconds. Another strength was the fact that the accelerometers were thigh mounted which allowed for the investigation of standing; a physical behaviour which has shown mixed results in randomised cross-over trials in terms of its impact on cardio-metabolic profile during prolonged sitting \[[@pone.0224223.ref022], [@pone.0224223.ref023], [@pone.0224223.ref051], [@pone.0224223.ref052]\]. Furthermore, the physical behaviour data in our study has allowed the investigation of the importance of the 10-minute criterion for MVPA, which is a current discussion point within the UK physical activity guidelines. Finally, the utilisation of isotemporal substitution analysis is essentially mathematical modelling of potentially effective physical behaviour change guidance, ultimately useful to both practitioners and end-users, as such analyses may assist with individualising physical behaviour programmes. It is nevertheless noted that given the cross-sectional study design, the presence of reverse causality bias for instance, cannot be ruled out. In addition to this, as this study was performed on a relatively small sample, some of the analysis may have been under-powered, increasing the chance of a type II error. An unsurmountable study limitation in this cross-sectional study design, was the fact that we could not stop participants taking pre-existing medications and indeed it would have been unrealistic and unrepresentative of an older population to have only recruited older persons on zero phamaceuticals. Whilst we applied statistical adjustment to this limitation by treating medication use as a covariate, the fact that we reduced this data to the categorical level means that the precision of our adjustment was limited. Future research should conduct this modelling with longitudinal data of a larger older adult sample size. We also recommend that future studies be statistically powered to recruit samples large enough to have sufficient numbers of participants using similar drug therapies. In this way, the amount and type of medication can be recorded and thus used at the ratio/interval level, thereby improving on the quality of adjustments.

Conclusion {#sec022}
==========

The current study added further evidence to support the 10-minute bout recommendation within the MVPA guidelines of PA for older adults, as well as highlighting that quantitative guidelines are required for reducing SB engagement in older adults. Finally, the current study has potentially shown that a PB can have both a positive and negative effect on cardio-metabolic status (though requiring further investigation), dependent on what PB it is replacing. Thus, advocating the need for individualised interventions, where possible, that account for the participant's habitual PB engagement, rather than a one size fits all approach.

Supporting information {#sec023}
======================

###### Effect of PB on fasting plasma LOG cholesterol concentration according to isotemporal substitution of one hour per day of SB or PA.
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Click here for additional data file.

###### Effect of PB on fasting plasma LOG triglyceride concentration according to isotemporal substitution of one hour per day of SB or PA.
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###### Effect of PB on fasting serum LOG LPL concentration according to isotemporal substitution of one hour per day of SB or PA.
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###### Effect of PB on fasting plasma glucose concentration according to isotemporal substitution of one hour per day of SB or PA.
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###### Effect of PB on fasting plasma HbA1c according to isotemporal substitution of one hour per day of SB or PA.
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###### Effect of PB on fasting serum LOG IL-6 concentration according to isotemporal substitution of one hour per day of SB or PA.
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###### Effect of PB on fasting serum LOG PIIINP concentration according to isotemporal substitution of one hour per day of SB or PA.
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Click here for additional data file.
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